Product image of Metoject (Methotrexate) supplied by GNH India

Metoject

Active Ingredient:
Methotrexate
Origin:
EU

Metoject (Methotrexate)

Methotrexate, the active ingredient in Metoject, is an antimetabolite (folate antagonist) presented as a subcutaneous formulation for injection use. It is employed to treat autoimmune disorders and certain cancers in adult patients.
GNH India supplies Metoject as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Medac Gesellschaft Für Klinische Spezialpräparate Mbh (Wedel)

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Metoject (Methotrexate) acts on rapidly dividing cells and modulates immune activity, making it useful for several disease groups.

  • Rheumatoid arthritis: reduces joint inflammation and slows structural damage.
  • Psoriasis: limits skin cell proliferation and improves plaque severity.
  • Acute lymphoblastic leukemia: interferes with malignant cell DNA synthesis to achieve remission.
  • Lymphoma: inhibits growth of malignant lymphoid cells, supporting disease control.

How It Works

  • Methotrexate inhibits the enzyme dihydrofolate reductase, decreasing tetrahydrofolate production and thereby limiting purine and pyrimidine synthesis. This reduction in DNA, RNA, and protein synthesis impairs the replication of rapidly dividing cells and modulates immune cell activity, contributing to its immunosuppressive and antineoplastic effects.

Side Effects

Metoject may cause a range of adverse reactions, from mild to severe.

Common Side Effects

  • Nausea or vomiting: gastrointestinal upset that may be transient.
  • Fatigue: feeling of tiredness or reduced energy.
  • Mouth sores: ulceration of oral mucosa.
  • Elevated liver enzymes: mild hepatic enzyme rise on laboratory testing.
  • Low blood cell counts: mild reductions in white cells or platelets.

Serious or Rare Side Effects

  • Severe liver toxicity: potential for hepatitis or fibrosis.
  • Pulmonary fibrosis: progressive lung scarring affecting breathing.
  • Bone marrow suppression: profound pancytopenia requiring medical intervention.
  • Renal impairment: decreased kidney function leading to drug accumulation.
  • Severe cutaneous reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Precautions & Warnings

Before using Metoject, consider the following safety measures.

  • Pregnancy: contraindicated in pregnancy (Category X) due to teratogenic risk.
  • Liver function: monitor hepatic enzymes regularly; avoid use in severe liver disease.
  • Renal function: assess creatinine clearance; dose adjustment may be needed.
  • Blood counts: perform complete blood count monitoring to detect cytopenias.
  • Infections: screen for latent infections and avoid use in active severe infections.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Methotrexate can interact with several medicines, altering its efficacy or safety.

Major Interactions (Avoid)

  • Non‑steroidal anti‑inflammatory drugs (NSAIDs): increase methotrexate toxicity.
  • Proton pump inhibitors (e.g., omeprazole): may raise serum methotrexate levels.
  • Trimethoprim‑sulfamethoxazole: enhances risk of bone‑marrow suppression.

Moderate Interactions (Monitor Closely)

  • Azathioprine or mycophenolate: additive immunosuppression requiring blood count monitoring.
  • Live vaccines: reduced efficacy and potential infection risk.
  • Penicillins (high‑dose): may decrease methotrexate clearance.

Frequently Asked Questions

Metoject, which contains methotrexate, is prescribed for rheumatoid arthritis, moderate to severe plaque psoriasis, acute lymphoblastic leukemia and certain types of lymphoma. In each case the drug works by reducing abnormal cell proliferation or modulating the immune response.

Methotrexate blocks the enzyme dihydrofolate reductase, lowering tetrahydrofolate levels needed for DNA, RNA and protein synthesis. This action slows the growth of rapidly dividing cells and dampens immune system activity, providing therapeutic effects in autoimmune diseases and cancers.

The dose of Metoject is individualized by the prescribing clinician based on the specific indication, patient weight, renal function and treatment response. Only a qualified healthcare professional should determine the appropriate dosing regimen.

Metoject is classified as Pregnancy Category X because it can cause severe fetal malformations and miscarriage. It is also contraindicated while breastfeeding, as methotrexate can be excreted in milk and harm the infant.

To request Metoject, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Compared with biologic DMARDs, methotrexate (Metoject) is a small‑molecule agent that is generally less expensive and administered by subcutaneous injection. It may be used alone or in combination with biologics, offering a different safety profile and the ability to modulate disease activity early in treatment.

Metoject should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. Keep the product in its original packaging until use to maintain stability and potency.

Metoject is given as a subcutaneous injection, typically into the abdomen or thigh. The injection site should be rotated to reduce local irritation, and the medication is administered by a qualified healthcare professional or trained patient following aseptic technique.

Serious risks include severe liver toxicity, pulmonary fibrosis, profound bone‑marrow suppression leading to pancytopenia, and renal impairment. Patients should be monitored regularly for liver enzymes, lung function, blood counts and kidney function to detect these complications early.

Metoject is contraindicated in pregnant women, individuals with severe liver or renal disease, active serious infections, and patients with known hypersensitivity to methotrexate or any component of the formulation. It should also be used with caution in patients with pre‑existing blood‑cell abnormalities.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Methotrexate

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT